Opportunity-Rich Pharmaceuticals Pipeline
Water Tower Research hosted InMed’s CEO and President Eric. A. Adams for a fireside chat on January 25, 2024. The discussion, hosted by Jesse Redmond, Managing Director at Water Tower Research, focused on InMed’s pharmaceutical pipeline in Alzheimer’s and age-related macular degeneration (AMD) and upcoming 2024 milestones in both its pharmaceutical drug development programs and in BayMedica’s health and wellness initiatives. This report contains a transcript of the conversation, which can be accessed on demand via a link in our full report and on our website. Promising new drug development candidates. Adams shared his excitement on the two new additions to InMed’s pharmaceutical development pipeline, which the company unveiled last quarter: INM-901 for Alzheimer’s and INM-089 for AMD. Both cannabinoid analog-based candidates offer novel approaches to diseases that are currently incurable. Unique multi-modal approach to Alzheimer’s. Although still in the very early development stage, preclinical data from in vitro and in-vivo provide early signals that INM-901 can positively affect four areas that are believed to be at the root of Alzheimer’s disease, reducing amyloid beta plaque and neuroinflammation, as well as increasing neuroprotective effects and enhancing neurogenesis (i.e. neurite outgrowth). The current treatment landscape at best slows the progress of Alzheimer’s but does not reverse it, and focuses on more limited treatment pathways, notably amyloid beta plaque. Glaucoma work yields promising AMD treatment research pathway. InMed’s preclinical work in glaucoma (INM-088), which starts as a front-of-the-eye disease, has facilitated the advancement of preclinical work using another proprietary cannabinoid analog in InMed’s treasure chest of analogs for research for the treatment of AMD (INM-089), a back-of-the-eye disease. This is another significant market opportunity for InMed, with AMD affecting 200 million people worldwide. Pathways forward for opportunity-rich InMed. From a financial perspective, InMed has an advantage over many other similarly sized clinical-stage biotechs by already being a growing revenue-stage company via BayMedica’s commercial business and a cash runway through 2024. Still, with several exciting drug candidates in InMed’s pipeline, strategic partnerships and out-licensing opportunities are under consideration to facilitate their advancement. The next opportunity to hear from InMed will be when Jesse Redmond hosts Jerry Griffin, VP of Sales and Marketing for BayMedica, on The Water Tower Hour podcast on February 21, 2024.
Water Tower Research is built on the foundation of democratizing information flow. We bridge the growing information gap between companies and investors through our investor engagement strategies and open-access research platform.
Our research analysts are Wall Street veterans with the experience and knowledge to work with companies and investors in tandem. We provide access to the information and content that anchors the due diligence process for both professional money managers and individual investors. We leverage traditional research distribution channels and the best of modern digital strategies and tactics to amplify this information flow globally to engage all categories of investors and stakeholders.
Information flow is the foundation for creating investor awareness, knowledge, and engagement. Our mission is to help companies and investors have the tools they need and achieve their goals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.